Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INC424 vs best available therapy in polycythemia vera (HU-resistant/intolerant)
CTR20130865Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ruxolitinib in polycythemia vera (PV), sponsored by Novartis. Started Jul 2015; status: completed.
02
Drugs
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on CTR20130865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20130865.